All 2025 News
-
Experts highlight alcohol use and obesity as risk factors of breast cancer
Panelists examined the latest understanding about the connections between breast cancer and lifestyle factors, such as alcohol consumption and obesity.
-
Special session amplifies dialogue on lobular breast cancer
Presenters explored topics related to lobular breast cancer, including ILC-specific considerations for clinical trials, diagnostic criteria, and the role of adjuvant chemotherapy.
-
Second General Session reveals findings from de-escalation trials, preoperative radiotherapy study, and more
Gaorav Gupta, MD, PhD; Isabelle Bedrosian, MD; and Marjolein Smidt, MD, PhD, were among the experts reporting findings Thursday during the General Session at the San Antonio Breast Cancer Symposium.
-
Plenary panel outlines transformational role of patients and survivors as advocates, collaborators
Panelists discussed the vital role of patient advocacy in advancing breast cancer research, policy, and care.
-
SABCS Schedule Spotlight for Friday, December 12
Plan your Friday schedule and don’t miss notable items on the program, including the third General Session, the Beyond Cancer special session, and more.
-
Wrap up SABCS with signature review, recommendation sessions
The Year in Review and View from the Trenches sessions on Friday afternoon will feature can’t-miss insights about breast cancer research and clinical practice.
-
Surgeons to debate universal axillary staging in early breast cancer
Melissa Pilewskie, MD, and Walter Weber, MD, will explore opposing sides of the question “Do all patients with early-stage breast cancer need axillary staging?” during a Friday afternoon debate.
-
SABCS Snippets: Results of the INSEMA Trial
Mylin Torres, MD, talks with Prof. Dr. med. Guido Hildebrandt about the secondary results of the INSEMA trial, which evaluated applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy.
-
SABCS Snippets: Results of the BOOG 2013-08 Study
Marcela Mazo, MD, talks with Marjolein Smidt, MD, PhD, about the results of the Phase III BOOG 2013-08 trial, which indicate that sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer.
-
SABCS Snippets: Results of the Phase II SUMIT-BC Trial
Saba Shaikh, MD, talks with Sonia Pernas, MD, PhD, about the results of the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib combined with fulvestrant demonstrated promising efficacy in ER+/HER2- locally advanced or metastatic breast cancer patients previously treated using an aromatase inhibitor with a CDK4/6 inhibitor.